Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma.

@article{Alemao2011InversePW,
  title={Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma.},
  author={Evo Alemao and Srinivasan Rajagopalan and Shiyi Yang and Rafael E. Curiel and Joseph Purvis and Maiwenn J. Al},
  journal={Journal of medical economics},
  year={2011},
  volume={14 2},
  pages={245-52}
}
OBJECTIVE This post hoc analysis evaluated treatment-associated quality-adjusted survival (QAS) in patients randomly assigned to temsirolimus or interferon alfa (IFN-alfa), corrected for censoring using inverse probability weighting (IPW), in the Advanced Renal Cell Carcinoma (ARCC) trial. METHODS Follow-up was divided into 11 time intervals; Kaplan-Meier estimates for not being censored were estimated for each interval. The QAS for each interval was weighted by the inverse probability of not… CONTINUE READING